Johnson & Johnson plans to buy Dutch vaccine group

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

"The companies expect that Crucell's strength in the manufacture, discovery and commercialisation of vaccines would create a strong platform for Johnson & Johnson in the market," the two firms said in a statement.

"Under the terms of the negotiations... Johnson & Johnson or an affiliate would acquire all outstanding equity of Crucell that it does not already own for approximately euro 1.75 billion (2.30 billion dollars)," it added.

Johnson & Johnson already owns 17.5 percent of Crucell.

The US firm said it would keep Crucell's headquarters in Leiden in the Netherlands and preserve jobs at the Dutch company, which employs 1,300 people.

Lasy year Crucell produced more than 115 million vaccine doses in more than 100 countries, with the most of the treatments going to developing countries.


Explore further

Summer time and the living is breezy

(c) 2010 AFP

Citation: Johnson & Johnson plans to buy Dutch vaccine group (2010, September 17) retrieved 25 January 2020 from https://medicalxpress.com/news/2010-09-johnson-dutch-vaccine-group.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments